Octreotide Patient Care Program

Patients prescribed with ^PrOctreotide for Injectable Suspension have access to the bilingual Octreotide Patient Care Program^SM. By helping patients enrol, you ensure they receive the support they need while taking this medication.

The program contains two key components:

• Injection administration: ^PrOctreotide for Injectable Suspension must be administered intragluteally at 4-week intervals by a trained healthcare professional only. Injections will be scheduled in a clinic and administered by a nurse.
  
  
• Financial support:  In some cases, the Octreotide Patient Care Program^SM can provide patients with personalized financial solutions to help them get started with their treatment. A case manager will help patients navigate insurance and provide details on the financial assistance that is available. For patients who qualify, the pharmacy will be reimbursed in the same way as any other third-party plan.

How to enrol patients:

Prescribers, pharmacists, technicians or pharmacy assistants can initiate enrolment.  To enrol a patient, fax the completed enrolment form to 1-833-377-0557 or email it to OctreotidePatientCare@teva-canada.com. Bilingual case managers are available to guide you through the enrolment process and provide you with everything you need to get patients started on Octreotide for Injectable Suspension.

Resources designed to help explain the program and its benefits to patients:

Program details and how it works:  Use this document to gain a better understanding of the specific operation of the program and reimbursement process. 

Patient information letter: This letter outlines the services provided by the program to your patients.

If you have any questions about this program, please contact your Teva Canada Sales Representative or the Octreotide Patient Care case managers at 1-877-445-6984.